StockData
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc. (BDTX) stock

BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$1.44−0.09 (-5.88%)

Close on Nov 17, 2026Market cap $82.73MP/E –Yield –

Black Diamond Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Black Diamond Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $70.00M. The highest annual figure on record is $70.00M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$70.00M–
FY2024Dec 31, 2024$0–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$70.00M–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–
Q2 FY2019Jun 30, 2019$0–
Q1 FY2019Mar 31, 2019$0–
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–

More Black Diamond Therapeutics figures

See a number that looks wrong?